{"entity":{"id":"nct05850234","kind":"trial","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","aka":[],"tldr":"A phase 1/2 trial of AZD0120 in multiple myeloma, run by AstraZeneca, now recruiting.","summary":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) is a phase 1/2 interventional study registered as NCT05850234 by AstraZeneca, with 232 participants planned, started 2023-07-20 and due to reach its primary completion in 2027-10-01. Interventions recorded: AZD0120.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05850234","url":"https://clinicaltrials.gov/study/NCT05850234"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["azd0120"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05850234","phase":"1/2","setting":"A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)","sponsor":"AstraZeneca","enrolled":232,"outcomes":[]},"route":"/trials/nct05850234/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"azd0120","kind":"drug","name":"AZD0120","route":"/drugs/azd0120/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}